Articles tagged with Ovarian Cancer
Introgen presents Phase I trial results on RPR/INGN 201, showing safety and expression in ovarian cancer, lung carcinoma, and glioblastoma patients. The therapy has demonstrated significant potential in treating these life-threatening conditions.
The company presented Phase II data of tgDCC-E1A, a lead cancer therapy, which showed a 45% objective response rate in patients with recurrent head and neck squamous cell carcinoma. Preclinical studies also demonstrated the ability of E1A to sensitize tumors to radiation and chemotherapy.
The data from an ongoing Phase 1/2 trial of O-Vax in patients with advanced ovarian cancer indicates that the vaccine induces a positive immunological response, as measured by a delayed type hypersensitivity test. Favorable clinical responses were also observed, including complete regression of tumors and normalization of CA-125 levels.
Researchers have reported promising results from a Phase I-II trial of an ovarian cancer vaccine made from patient's own cancer cells. Eight of 10 patients showed immunological response, with one experiencing complete tumor disappearance and CA125 levels normalization.
Three Cedars-Sinai physicians are leading a fight against women's cancers through innovative research, clinical care, and genetic screenings. Beth Karlan focuses on curing and preventing ovarian cancer, while Maren Scheuner develops personalized prevention plans for breast, endometrial, and ovarian cancers.
A Northwestern University researcher is leading a five-year, $5 million National Cancer Institute-sponsored study to improve current methods and evaluate new tests for detecting early-stage ovarian cancer. The study aims to identify novel biomarkers that can detect ovarian cancer in its early stages.
Researchers at Fox Chase Cancer Center are conducting a clinical trial to investigate the efficacy of fenretinide, a vitamin A-related medicine, in preventing ovarian cancer. Women with high-risk factors for breast and ovarian cancer will take part in this study to examine the molecular effects of fenretinide on ovarian tissue.
Women at high risk for ovarian cancer experience depression when concerned about passing the disease to their daughters. A study found that 33% of participants were depressed during initial assessments and 38% during follow-ups, with concern for daughters being a leading source of distress.
The Pacific Ovarian Cancer Research Consortium aims to discover genes, develop a cancer vaccine, and improve treatment outcomes for ovarian cancer. The five-year study will involve researchers from several institutions and involve at least 3,500 women in its various studies.
A clinical trial at UNC is testing the effectiveness of LY353381, a selective estrogen receptor modulator (SERM), for treating ovarian and endometrial cancers. The drug has minimal side effects compared to traditional chemotherapy.
A study suggests that an imbalance in genes expressed on the X chromosome may lead to ovarian cancer development. The research found nonrandom X-chromosome inactivation in over 50% of women with invasive ovarian cancer, particularly those with BRCA1 mutations.
Researchers found that progestin activates apoptosis in the ovarian lining, preventing precancerous cells from becoming malignant. The study suggests that periodically administering progestin could be a highly effective preventive treatment for ovarian cancer.
A multi-center study provides clear guidelines for genetic testing in women with breast cancer, identifying those at high risk of ovarian cancer. The study found that nearly 40% of participants had abnormalities in BRCA1 and BRCA2 genes, associated with a 10-fold increase in ovarian cancer risk.
Researchers successfully delivered and expressed an E1A gene in both diseased and normal human cells using a proprietary non-viral liposomal delivery mechanism. The study showed decreased levels of surrogate tumor markers in three patients with breast and ovarian cancers, indicating potential as a treatment for various types of cancer.
Researchers at Thomas Jefferson University have created an autologous ovarian cancer vaccine that stimulates an immune response in patients, showing promise for treatment. The vaccine is custom-made for each patient and has been safe with no significant side effects, paving the way for further clinical trials.
Researchers found a strong link between increased ovulatory cycles and p53 genetic mutations in ovarian cancer. Women at high risk can protect themselves by reducing their ovulation through birth control, pregnancy, or breast-feeding.
A new study found that prophylactic surgery can prolong life expectancy by approximately 8.5 years, but at a significant impact on quality of life. The study also concluded that prophylactic surgery is cost-effective compared to cancer treatments.